Home » Stocks » EYEN

Eyenovia, Inc. (EYEN)

Stock Price: $5.05 USD -0.34 (-6.23%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $5.05 +0.01 (0.10%) Apr 16, 5:00 PM
Market Cap 129.27M
Revenue (ttm) 2.00M
Net Income (ttm) -19.77M
Shares Out 25.62M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $5.05
Previous Close $5.38
Change ($) -0.34
Change (%) -6.23%
Day's Open 5.41
Day's Range 5.03 - 5.42
Day's Volume 66,758
52-Week Range 2.55 - 7.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK--(BUSINESS WIRE)-- #EYEN--Dr. Julia Haller brings experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader to her role as an Eyenovia director.

2 weeks ago - Business Wire

Announces MydCombi expected PDUFA date of October 28, 2021

3 weeks ago - GlobeNewsWire

NEW YORK & CHICAGO--(BUSINESS WIRE)-- #MydCombi--Eyenovia has tapped EVERSANA as exclusive distributor of its MydCombi product for pupil dilation in the U.S., pending the product's FDA approval.

3 weeks ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #Optejet--Eyenovia's MAP™ fixed-combination pharmaceutical for pupil dilation has been shown to be safe, effective and superior in comparative study.

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #mydriasis--FDA accepts Eyenovia's NDA for MydCombi, a unique fixed combination pupil dilation agent delivered with the Optejet. PDUFA date is expected 4Q 2021.

1 month ago - Business Wire

The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET The webinar, “Presbyopia in Focus: Unlocking On...

2 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia consultant Dr. David Wirta will speak at the Ophthalmology Innovation Summit Presbyopia Innovation Showcase on January 28.

2 months ago - Business Wire

Today, we revisit a promising small ocular biopharma concern called Eyenovia for the first time in almost 18 months. The company continues to advance its pipeline and recently submitted a marketing appl...

3 months ago - Seeking Alpha

NEW YORK--(BUSINESS WIRE)-- #FDA--Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.

3 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia has enrolled its first patients in the Phase 3 VISION-1 Study of MicroLine for the improvement in near vision in patients with presbyopia.

4 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia obtains FDA acceptance of its IND application for MicroLine, a therapy designed for improvement in near vision in patients with presbyopia.

4 months ago - Business Wire

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day

5 months ago - GlobeNewsWire

Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.

Other stocks mentioned: BHC
6 months ago - Zacks Investment Research

Company reaffirms near term milestones for the Mydcombi™ (MicroStat) NDA and the MicroLine presbyopia program Phase III results

6 months ago - GlobeNewsWire

One year ago, I recommended Eyenovia's stock based on the company's effort in addressing several ophthalmic needs. Since that time, the stock has stagnated yet two collaborations have been announced.

6 months ago - Seeking Alpha

LAVAL, QC and NEW YORK, Oct. 12, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, its leading global eye health business, and Eyenovia, Inc., (NASDAQ: ...

6 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)-- #AAOPT--Drs. Siddarth Rathi, April Jasper to present latest analyses and updates from Eyenovia's clinical studies at the American Academy of Optometry 2020

6 months ago - Business Wire

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...

7 months ago - GlobeNewsWire

NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...

7 months ago - GlobeNewsWire

NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...

7 months ago - GlobeNewsWire

NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...

7 months ago - GlobeNewsWire

NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...

8 months ago - GlobeNewsWire

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Eyenovia (EYEN) is in the news Tuesday after an exclusive deal with Arctic Vision for two of its treatments sent EYEN stock soaring higher. The post Eyenovia News: Why EYEN Stock Is Skyrocketing 33% Tod...

8 months ago - InvestorPlace

Eyenovia Inc. (NASDAQ: EYEN) shares soared on Tuesday after the company announced an exclusive license agreement with Artic Vision to develop and commercialize its MicroPine for the treatment of progres...

8 months ago - 24/7 Wall Street

NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...

8 months ago - GlobeNewsWire

NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...

9 months ago - GlobeNewsWire

NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented p...

10 months ago - GlobeNewsWire

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented ...

10 months ago - GlobeNewsWire

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented p...

11 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor Eyenovia

11 months ago - Zacks Investment Research

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented p...

1 year ago - GlobeNewsWire

NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...

1 year ago - GlobeNewsWire

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented ...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).

1 year ago - Zacks Investment Research

Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Other stocks mentioned: ACIU, ASND, NGM, SAGE
1 year ago - Zacks Investment Research

Defers development activities of MicroProst and MicroTears

1 year ago - GlobeNewsWire

Eyenovia is a specialty ophthalmic company targeting several ophthalmic needs, including progressive myopia and presbyopia.

1 year ago - Seeking Alpha

NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented ...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...

1 year ago - GlobeNewsWire

Today, we take an in-depth look at a microcap 'Busted IPO' named Eyenovia.

1 year ago - Seeking Alpha

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2019 - Earnings Call Transcript

1 year ago - Seeking Alpha

CEO of Eyenovia Inc (30-Year Financial, Insider Trades) Tsontcho Ianchulev (insider trades) bought 233,813 shares of EYEN on 07/11/2019 at an average price of $2.78 a share.

1 year ago - GuruFocus

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About EYEN

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print (MAP) platform technology. The company focuses on to develop clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its pipelines focus on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceut... [Read more...]

Industry
Biotechnology
IPO Date
Jan 25, 2018
Stock Exchange
NASDAQ
Ticker Symbol
EYEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Eyenovia stock is "Buy." The 12-month stock price forecast is 12.50, which is an increase of 147.77% from the latest price.

Price Target
$12.50
(147.77% upside)
Analyst Consensus: Buy